Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis Q1 hit by H1N1

Sanofi-aventis has seen its first-quarter financial results hit by lack of flu vaccine and generic competition

Sanofi-aventis (SA) has reported a 16.1 per cent fall in net income to €2.2bn at CER for the first quarter of 2011.

The company posted a 5.2 per cent decline in first-quarter sales to €7.8bn in 2011, including €569m of sales lost in 2011 due to generic competition,.

However, excluding A/H1N1 sales its first-quarter sales rose by 0.1 per cent.

The company said emerging markets sales increased by 14.6 per cent (excluding A/H1N1 sales) to €2.4bn, exceeding the US and Western Europe, and accounted for 30.7 per cent of group sales.

Christopher A Viehbacher, CEO, S-A, said: "This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I'm particularly satisfied with the performance of our growth platforms which were up 15.5 per cent (excluding A/H1N1) and now represent almost 60 per cent of group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company."

S-A's EPS was €1.66, down 16.1 per cent at CER. Excluding A/H1N1 sales, the decrease in business EPS was limited to 6.0 per cent at CER.

28th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics